CPT code 19086: MRI-guided breast biopsy add-on billing guide
CPT code 19086 bills each extra lesion in an MRI-guided breast biopsy, always wi...
Last Updated: August 14, 2026
Key takeaways
CPT code 19086 is the add-on code for percutaneous breast biopsy under magnetic resonance guidance, reported once for each additional lesion.
It is always billed with parent code 19085, and it is never valid on its own.
MR guidance is bundled into the pair, so CPT 77021 is not reported separately with 19085 or 19086.
Stereotactic guidance belongs to 19081 and 19082, and ultrasound guidance to 19083 and 19084.
CMS article A57848 covers tomosynthesis-guided biopsy, so it is the wrong citation for an MRI-guided claim.
Practice management software like Pabau pre-fills the claim from the record and checks the insurer details before you send it.
Two enhancing lesions show up on a contrast-enhanced breast MRI. Both get sampled in the same session. Then the claim goes out with a single code on it, and the second lesion goes unpaid.
CPT code 19086 is the line that captures that second lesion. It covers each additional lesion biopsied under magnetic resonance guidance, and it only travels with CPT 19085.
Two habits break it. One is leaving the parent code off the claim. Another is reaching for whichever biopsy pair you use most often. Both are easy to catch before the file leaves your practice.
CPT code 19086 covers every lesion after the first
CPT code 19086 covers percutaneous breast biopsy performed under magnetic resonance guidance, for each additional lesion beyond the first. The American Medical Association (AMA) maintains the CPT code set, and it prints this descriptor in two parts. One parent statement runs across the whole 19081 to 19086 family, then each code adds its own line.
Three things decide whether CPT code 19086 applies. The guidance has to be magnetic resonance, not ultrasound and not stereotactic. Next, the lesion has to be the second or a later one sampled in that session. Placement of a localization device and specimen imaging are already included when they happen, so neither gets billed on its own.
19086 never goes on a claim without 19085
The most common denial trigger is a claim that carries the add-on without its parent. These codes are a pair, so 19086 has to sit under 19085 on the same claim.
Two lesions sampled under MRI guidance read as 19085 for the first and 19086 x1 for the second. Three lesions read as 19085 plus 19086 x2. So the add-on repeats once per lesion after the first, and it never covers the initial biopsy.
Guidance itself is bundled into both codes. Do not report CPT 77021, magnetic resonance guidance for needle placement, alongside 19085 or 19086. Specimen imaging is bundled the same way when it happens, which is what the phrase “when performed” signals in the descriptor.
The guidance in the room decides which pair you bill
Codes 19081 through 19086 cover percutaneous image-guided breast biopsy across three modalities. Each modality has a primary code for the first lesion and an add-on for every lesion after it. Stereotactic work starts with CPT 19081, ultrasound work with 19083, and MRI work with 19085.
Mixed-modality sessions trip up otherwise clean claims. Say the first lesion is sampled under ultrasound and the second under MRI. The claim then reads CPT 19083 plus 19085, never 19083 plus 19086. An ultrasound second lesion takes CPT 19084 instead, because an add-on only ever follows the primary from its own pair.
One unit of 19086 for every extra lesion sampled
Report CPT code 19086 once for every lesion biopsied after the first in the same session. CPT sets no fixed cap on units, so three additional lesions means three units. Each one needs its own documentation.
A contralateral lesion counts as an additional lesion rather than a second primary. Say the first lesion sits in the right breast and the second in the left, both under MRI guidance. The claim reads 19085 for the first lesion and 19086 for the contralateral one. Laterality modifiers then tell the payer which side each line describes.
Other breast add-ons count the same way. CPT 19001 repeats for each extra cyst aspirated in one visit. Whatever the code, the habit is the same. Count the lesions in the note, then count the lines on the claim.
Unit limits still bite in practice. CMS publishes medically unlikely edit (MUE) values quarterly, and a line above the current value suspends for record review. Check the MUE table for 19086 before you submit a high-unit claim. Commercial payers apply their own thresholds too.
What Medicare pays depends on setting and locality
Medicare pays CPT code 19086 through the Medicare Physician Fee Schedule (MPFS), which the Centers for Medicare and Medicaid Services (CMS) administers. Two things move the rate. The first is the setting where the work happens, and the second is your geographic locality.
Pricing a line for your own market takes four steps:
- Pull the work, practice expense and malpractice RVU values for 19086 from the fee schedule lookup.
- Multiply each RVU by the matching geographic practice cost index (GPCI) value for your locality.
- Add the three adjusted figures together, then multiply the total by that year’s conversion factor.
- Use the facility figure for hospital outpatient and ASC work, and the non-facility figure for office work.
The facility rate sits lower because the hospital bills the overhead on its own claim. As an add-on, 19086 carries RVUs for the incremental work of the extra lesion, not for a full procedure. Teams billing breast procedures inside a plastic surgery practice should confirm locality rates each January, when the schedule updates.
Pro Tip
Check your Medicare Administrative Contractor (MAC) fee schedule as well as the national average. MACs apply locality GPCI values that move reimbursement in both directions. Coastal urban markets often sit above the national figure, while rural localities in the Midwest and South often sit below it. Pull the number for your own locality before you build a revenue forecast on 19086.
LT and RT belong on the line, 51 never does
Three modifiers matter on a 19086 line, and one of them is a trap. LT and RT report the side. Modifier 59 has a narrow, defensive use. As for 51, it never applies, because add-on codes are exempt from the multiple-procedure reduction.
Payers expect laterality on breast procedure codes, because they have to know which side was treated. Apply LT or RT to 19086 the same way you apply it to 19085. Lesions in the same breast carry the same modifier on both lines, while a contralateral lesion carries the opposite one.
Modifier 59 is a defensive tool, not a routine one. Some commercial payers do not follow AMA add-on logic, and their edits flag 19086 anyway. Use 59 only where the record clearly supports a distinct service, and check the payer policy first.
The diagnosis has to justify that specific lesion
Every 19086 line needs a diagnosis code that carries medical necessity for the lesion on that line. MRI-guided biopsy usually follows an enhancing finding that only the MRI can see, so these pairings differ from the ones used on mammographic work.
The last three codes come from surveillance rather than symptoms. High-risk screening often starts in an OB-GYN practice, where the family history and genetic results already sit on file. Once pathology confirms cancer, later encounters move to a code such as C50.411.
Code to the highest level of specificity the record supports at the time of the procedure. Where the MRI report gives laterality and quadrant, use a code that carries both. Unspecified codes are accepted when the location is genuinely not established, though they attract more scrutiny on audit.
Match the diagnosis on the add-on line to the lesion that line describes. Copying the first lesion’s diagnosis onto every unit of 19086 makes a multi-lesion claim harder to defend.
Coverage for MRI-guided biopsy sits with your MAC
No national Medicare policy names MRI guidance for percutaneous breast biopsy. NCD 220.13, Percutaneous Image-Guided Breast Biopsy, has covered this work since January 2003, and it names stereotactic or ultrasound imaging only. Coverage for the MRI-guided pair therefore sits with each Medicare Administrative Contractor.
One citation is worth correcting, because it circulates widely on breast biopsy pages. CMS article A57848, Billing and Coding: Tomosynthesis-Guided Breast Biopsy, addresses tomosynthesis-guided work. That falls to the stereotactic pair, 19081 and 19082, or to unlisted code 19499. Quoting it in an MRI appeal weakens the appeal.
Look up your own contractor’s policy in the CMS Medicare Coverage Database before the procedure date. Where a contractor publishes nothing specific to MRI-guided biopsy, necessity is judged on the clinical record alone. Payers generally expect that record to show:
- A contrast-enhanced breast MRI identifying a suspicious enhancing lesion that needs tissue sampling
- Evidence the lesion is not visible on targeted second-look ultrasound or mammography, which would move the biopsy to 19083 or 19081
- Tissue obtained from every lesion billed, with a pathology specimen for each
- A localization marker placed and confirmed on post-procedure imaging, where placement was performed
- A practitioner trained in MRI-guided breast biopsy performing or supervising the procedure
Most of that evidence comes together before the patient reaches the biopsy suite. Suspicious findings often pass through a multidisciplinary review first, and that discussion belongs in the record alongside the MRI report.
Coverage limits follow the same logic across contractors. A biopsy without an imaging finding to justify it will not meet necessity. Palpable lesions that can be sampled without image guidance are also hard to defend under these codes. Keeping those records HIPAA-compliant is a baseline requirement, not an optional extra.
Sequence the claim first, document every lesion second
Clean 19086 claims come down to two things. The claim needs the right line-item sequence, and the note needs to name every lesion. It helps to picture how the file moves.
The radiologist dictates the MRI report and the procedure note. A coder reads both, then builds the claim with 19085 on line one and 19086 on line two. Charge entry adds LT or RT to each line.
From there the file hits the clearinghouse, which screens it before the payer ever sees it. An add-on with no primary above it stops at that point. These five steps prevent most first-pass denials.
- List 19085 first on the claim. CPT code 19086 belongs on the line after its parent. Clearinghouse edits reject an add-on that appears without its primary, or ahead of it.
- Apply laterality modifiers to both lines. A left-breast session carries LT on 19085 and on 19086. Inconsistent laterality between primary and add-on is a common edit trigger.
- Document each lesion separately. The MRI report and procedure note should name every biopsied lesion by quadrant or clock position and depth. Each note should also record the marker placed in that lesion.
- Keep MR guidance and specimen imaging bundled. CPT 77021 is not reported with 19085 or 19086, and specimen imaging is not unbundled either, unless a payer policy specifically allows it.
- Attach the MRI report. The contrast-enhanced study that identified the lesions establishes the indication. A missing report is the second most common cause of denial, behind sequencing errors.
Pro Tip
Build a pre-submission check for multi-lesion MRI cases. Confirm 19085 is the primary, count the additional lesions, and confirm one unit of 19086 per additional lesion. Check that laterality modifiers match across every line, that CPT 77021 is not on the claim, and that the MRI report names each lesion separately. A one-minute review clears most 19086 denials before they happen.
The errors that stall a 19086 claim, and their fixes
The rule set behind CPT code 19086 is narrow, which makes its denial patterns predictable. Here are the errors that show up most often, with the fix for each.
- Billing 19086 without 19085. An add-on cannot stand alone, so the line auto-denies when the primary is missing. Confirm 19085 is on the claim before submission.
- Using the wrong pair for the guidance modality. Reporting 19086 for a lesion sampled under ultrasound or stereotactic guidance is a coding error and an upcoding risk. Match the modality to its pair before you code the session.
- Citing CMS article A57848 in an MRI appeal. That article governs tomosynthesis-guided biopsy, which is stereotactic work. Quoting it on a 19086 denial hands the reviewer a reason to close the appeal.
- Applying modifier 51. Add-on codes are modifier 51 exempt by definition. Appending it triggers a payment reduction that should never apply.
- Unbundling guidance or specimen imaging. CPT 77021 and separate specimen imaging codes are already paid inside 19085 and 19086. Billing them again is a compliance risk.
- Vague or missing ICD-10 diagnosis codes. A diagnosis that does not match the lesion on that line invites review. Pull the wording straight from the MRI report.
- Inconsistent laterality modifiers. LT on 19085 and RT on 19086 tells the payer two sides were treated. Without documentation for both, the claim stalls.
How Pabau keeps multi-lesion biopsy claims complete
Billing 19086 by hand depends on someone remembering that a second lesion was sampled. The coder then finds the parent code, matches the modifiers and checks each diagnosis, working from someone else’s note. Every one of those steps is a chance to lose the add-on.
Practice management software like Pabau keeps the record and the claim in one place. Pabau’s claims management software pre-fills the claim from the record, so the codes attached to the service land on the charge lines. Coders also get CPT and ICD-10 lookup libraries on the same screen.
Before a claim can go out, Pabau checks that the required insurer fields are complete, including membership numbers and authorization codes. It then submits the claim electronically and tracks its status, so your team sees a denial without chasing the payer.
Counting the lesions still belongs to your team. Pabau’s medical records management holds the note and the charge lines on one client record. A session that sampled three lesions and billed only two is then easy to spot on review.
Send breast biopsy claims that are complete
Pabau’s claims management software pre-fills each claim from the clinical record and checks the required insurer details before submission. Your team spends less time rebuilding claims that came back.
Conclusion
Payment on a multi-lesion MRI biopsy is won or lost in the minute between the procedure note and the charge entry. Get the pair right, count the lesions, match the laterality, and 19086 pays without an appeal.
So the practical move is to standardize that minute. Give the coder a note that names every lesion, then give the claim a sequence check before it leaves. One trade-off is worth remembering. MRI-guided biopsy has no national coverage policy, so your contractor decides the borderline cases.
Practices that keep the note and the claim in one system lose fewer add-on lines along the way. Book a demo to see how Pabau handles claim details for radiology and breast surgery teams.
Continue your research
Working the stereotactic side of the family? CPT code 19081 covers the primary code for stereotactic breast biopsy, with the same pairing rules.
Billing the marker as well as the biopsy? CPT code 19285 explains when breast localization device placement is reported on its own.
Counting add-on units on another breast procedure? CPT code 19001 walks through the add-on for each additional cyst aspirated in one visit.
Documenting the meeting that sent the patient to biopsy? Multidisciplinary review template gives you a structure for recording the decision and who made it.
Frequently asked questions
Does CPT 19086 need prior authorization?
It depends on the payer. Medicare has no national policy for MRI-guided breast biopsy, so authorization rules sit with your MAC. Many commercial plans do require it, so check before the procedure date.
Can 19086 be used for a lesion biopsied on another day?
No. The add-on only covers extra lesions sampled in the same session. A biopsy on another day is a new claim, with its own primary code.
Who bills 19086 when the biopsy happens in a hospital?
The physician bills 19086 on the professional claim, paid at the facility rate. The hospital reports its own charges on a separate facility claim.
Does 19086 have its own global period?
No. It carries a ZZZ global period, which means it follows the global period attached to 19085. Post-procedure care is handled under the primary code.
What if the pathology comes back benign?
Nothing changes on the claim. Medical necessity rests on the imaging finding that led to the biopsy, not on the pathology result. Keep the MRI report with the record.
